OXFORD, England—October 31, 2022 04:00 AM Eastern Daylight Time—Ochre Bio, an innovator in chronic liver disease drug development, today announced its participation in upcoming investor and industry conferences.
WebSummit
Presentation Title: Why you should love your liver
Date/Time: Nov 4, 1:36 WET – 1:47 pm Western European Time
Location: The Altice Arena and FIL, Rossio dos Olivais, 1990-231 Lisbon, Portugal
Presenter: Jack O’Meara, CEO & Co-Founder, Ochre Bio
Big Data and AI Innovation in Drug Discovery
Artificial Intelligence (AI) and big data approaches in drug discovery have gained substantial momentum over the past few years, with the benefit of speeding up drug development timelines as well as reducing research costs. Ochre Bio employs genomics-led target discovery and human-based preclinical models and RNA medicine to develop new therapies for chronic liver diseases. Seeing the infinite potential of AI and big data’s involvement in drug development, Ochre Bio will hold a symposium in Taipei, Taiwan on this trending topic.
Date/Time: Wednesday, Nov. 9, 9:30-12:15 pm
Location: 2nd Floor, Building C, National Biotechnology Research Park , No. 99, Lane 130, Section 1, Institute Road, Nangang District, Taipei, Taiwan
Symposia Information: https://geneonline.news/ochre-bio-ai-big-data-symposium/
Agenda and registration: https://forms.gle/gQeiQaPbexY7ACqy9
Speakers include industry leaders in the field of big data, genomics and drug development:
- Dr. Quin Wills, CSO of Ochre Bio
- Dr. Jimmy Lin, CEO of Insilico Medicine Taiwan
- Dr. Inca Chen, RD Manager of Acer
- Prof Liao, CEO of Syncell
